vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $16.9M, roughly 1.1× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 740.1%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-37.8M).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
FVCB vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $19.1M |
| Net Profit | — | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | 43.7% | -186.1% |
| Net Margin | — | -90.7% |
| Revenue YoY | 4377.5% | 740.1% |
| Net Profit YoY | — | 55.5% |
| EPS (diluted) | $0.31 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | — | ||
| Q3 25 | $416.0K | — | ||
| Q2 25 | $15.8M | $19.1M | ||
| Q1 25 | $382.0K | — | ||
| Q4 24 | $378.0K | $12.8M | ||
| Q3 24 | $412.0K | $29.1M | ||
| Q2 24 | $415.0K | — | ||
| Q1 24 | $359.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | $5.6M | — | ||
| Q2 25 | $5.7M | $-17.4M | ||
| Q1 25 | $5.2M | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | $4.7M | $-16.6M | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $1.3M | — |
| Q4 25 | 43.7% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 45.9% | -186.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 1341.1% | — | ||
| Q2 25 | 36.0% | -90.7% | ||
| Q1 25 | 1352.1% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | 1133.3% | -57.2% | ||
| Q2 24 | 1001.2% | — | ||
| Q1 24 | 373.3% | — |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.31 | — | ||
| Q2 25 | $0.31 | $-0.15 | ||
| Q1 25 | $0.28 | — | ||
| Q4 24 | $0.27 | $-0.91 | ||
| Q3 24 | $0.25 | $-0.18 | ||
| Q2 24 | $0.23 | — | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $778.5M |
| Total Assets | $2.3B | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $739.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $253.6M | — | ||
| Q3 25 | $249.8M | — | ||
| Q2 25 | $243.2M | $778.5M | ||
| Q1 25 | $242.3M | — | ||
| Q4 24 | $235.4M | $757.5M | ||
| Q3 24 | $230.8M | $378.9M | ||
| Q2 24 | $226.5M | — | ||
| Q1 24 | $220.7M | — |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.2B | $815.1M | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | $864.6M | ||
| Q3 24 | $2.3B | $439.2M | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $2.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-37.7M |
| Free Cash FlowOCF − Capex | $23.8M | $-37.8M |
| FCF MarginFCF / Revenue | 140.7% | -197.2% |
| Capex IntensityCapex / Revenue | 0.3% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $3.3M | $-37.7M | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $18.2M | $-37.5M | ||
| Q3 24 | $4.7M | $-12.5M | ||
| Q2 24 | $1.6M | — | ||
| Q1 24 | $7.2M | — |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $3.3M | $-37.8M | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $18.1M | $-37.5M | ||
| Q3 24 | $4.6M | $-12.6M | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | 140.7% | — | ||
| Q3 25 | 1818.0% | — | ||
| Q2 25 | 20.8% | -197.2% | ||
| Q1 25 | 1413.6% | — | ||
| Q4 24 | 4786.0% | -293.5% | ||
| Q3 24 | 1121.8% | -43.2% | ||
| Q2 24 | 361.2% | — | ||
| Q1 24 | 1988.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 37.3% | 0.0% | ||
| Q3 24 | 14.1% | 0.3% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | 3.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
